Parkinson's Disease
December 2022 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Parkinson's Disease abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Parkinson's Disease. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Parkinson's Disease. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Parkinson's Disease every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Probiotics for constipation in Parkinson's: A systematic review and meta-analysis of randomized controlled trials.
Authors:Yin S, Zhu F
Institution:Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.; Traditional Chinese Medicine Department, Zigong First People's Hospital, Zigong, China.
Journal:Front Cell Infect Microbiol. 2022 Nov 10;12:1038928. doi: 10.3389/fcimb.2022.1038928. eCollection 2022.

2:Migraine, Tension-Type Headache and Parkinson's Disease: A Systematic Review and Meta-Analysis.
Authors:Angelopoulou E, Papadopoulos AN, Spantideas N, Bougea A
Institution:Department of Neurology, Medical School, Eginition Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Journal:Medicina (Kaunas). 2022 Nov 20;58(11):1684. doi: 10.3390/medicina58111684.

3:The Role of Diet and Dietary Patterns in Parkinson's Disease.
Authors:Knight E, Geetha T, Burnett D, Babu JR
Institution:Department of Nutritional Sciences, Auburn University, Auburn, AL 36849, USA.
Journal:Nutrients. 2022 Oct 25;14(21):4472. doi: 10.3390/nu14214472.

4:Neuropathic Pain in Parkinson's Disease.
Authors:Cortes-Altamirano JL, Reyes-Long S, Bandala C, Morraz-Varela A, Bonilla-Jaime H, Alfaro-Rodriguez A
Institution:Division de Neurociencias, Instituto Nacional de Rehabilitacion 'Luis Guillermo Ibarra' (INR) Secretaria de Salud (SSA), CDMX; Departamentp de Quiropractica, Universidad Estatal del Valle de Ecatepec (UNEVE), Ecatepec de Morelos, Estado de Mexico, Mexico.; Division de Neurociencias, Instituto Nacional de Rehabilitacion 'Luis Guillermo Ibarra' (INR) Secretaria de Salud (SSA), CDMX, Mexico.
Journal:Neurol India. 2022 Sep-Oct;70(5):1879-1886. doi: 10.4103/0028-3886.359257.

5:Pharmacological management of Parkinson's disease motor symptoms: update and recommendations from an expert.
Authors:Kulisevsky J
Institution:Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Espana.
Journal:Rev Neurol. 2022 Oct 31;75(s04):S1-S10. doi: 10.33588/rn.75s04.2022217.

6:Management of psychiatric and cognitive complications in Parkinson's disease.
Authors:Weintraub D, Aarsland D, Biundo R, Dobkin R, Goldman J, Lewis S
Institution:Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.; ForeFront Parkinson's Disease Research Clinic, Brain and Mind Centre, School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia.
Journal:BMJ. 2022 Oct 24;379:e068718. doi: 10.1136/bmj-2021-068718.

7:Diagnosis and Treatment of Cognitive and Neuropsychiatric Symptoms in Parkinson Disease and Dementia With Lewy Bodies.
Authors:Weintraub D, Irwin D
Institution:
Journal:Continuum (Minneap Minn). 2022 Oct 1;28(5):1314-1332. doi: 10.1212/CON.0000000000001151.

8:Surgical Therapies for Parkinson Disease.
Authors:Rawls AE
Institution:
Journal:Continuum (Minneap Minn). 2022 Oct 1;28(5):1301-1313. doi: 10.1212/CON.0000000000001160.

9:Diagnosis and Medical Management of Parkinson Disease.
Authors:Thaler A, Alcalay RN
Institution:
Journal:Continuum (Minneap Minn). 2022 Oct 1;28(5):1281-1300. doi: 10.1212/CON.0000000000001152.

10:Tremor in Parkinson's Disease: From Pathophysiology to Advanced Therapies.
Authors:Abusrair AH, Elsekaily W, Bohlega S
Institution:Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.; Movement Disorders Program, Neurosciences Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Journal:Tremor Other Hyperkinet Mov (N Y). 2022 Sep 13;12:29. doi: 10.5334/tohm.712. eCollection 2022.

11:Clinical applications of exercise in Parkinson's disease: what we need to know?
Authors:Machado S, Teixeira D, Monteiro D, Imperatori C, Murillo-Rodriguez E, da Silva Rocha FP, Yamamoto T, Amatriain-Fernández S, Budde H, Carta MG, Caixeta L, de Sá Filho AS
Institution:Department of Sports Methods and Techniques, Federal University of Santa Maria, Santa Maria, Brazil.; Intercontinental Neuroscience Research Group, Merida, Mexico.
Journal:Expert Rev Neurother. 2022 Sep;22(9):771-780. doi: 10.1080/14737175.2022.2128768. Epub 2022 Sep 30.

12:Orofacial pain and dysfunction in patients with Parkinson's disease: A scoping review.
Authors:Verhoeff MC, Koutris M, Tambach S, Eikenboom D, de Vries R, Berendse HW, van Dijk KD, Lobbezoo F
Institution:Department of Orofacial Pain and Dysfunction, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Journal:Eur J Pain. 2022 Nov;26(10):2036-2059. doi: 10.1002/ejp.2031. Epub 2022 Sep 16.

13:Which type of mind-body exercise is most effective in improving functional performance and quality of life in patients with Parkinson's disease? A systematic review with network meta-analysis.
Authors:Mustafaoglu R, Ahmed I, Pang MYC
Institution:Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Istanbul University-Cerrahpasa, Buyukcekmece Yerle?kesi Alkent 2000 Mah. Yi?itturk Cad. No:5/9/1 Buyukcekmece, Istanbul, Turkey. rustem.mustafaoglu@iuc.edu.tr.; Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Hong Kong.
Journal:Acta Neurol Belg. 2022 Dec;122(6):1433-1446. doi: 10.1007/s13760-022-02070-4. Epub 2022 Sep 2.

14:Frailty and cognitive impairment in Parkinson's disease: a systematic review.
Authors:Sousa-Fraguas MC, Rodríguez-Fuentes G, Conejo NM
Institution:Department of Surgery and Medical-Surgical Specialties, Faculty of Medicine and Health Sciences, University of Oviedo, 33006, Oviedo, Spain. sousamaria@uniovi.es.; Laboratory of Neuroscience, Department of Psychology, University of Oviedo, 33003, Oviedo, Spain.
Journal:Neurol Sci. 2022 Dec;43(12):6693-6706. doi: 10.1007/s10072-022-06347-7. Epub 2022 Sep 2.

15:Longitudinal Studies of Sleep Disturbances in Parkinson's Disease.
Authors:Xu Z, Anderson KN, Pavese N
Institution:National Neuroscience Institute, Singapore, Singapore.; Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK. nicola.pavese@newcastle.ac.uk.
Journal:Curr Neurol Neurosci Rep. 2022 Oct;22(10):635-655. doi: 10.1007/s11910-022-01223-5. Epub 2022 Aug 26.

16:Lipid Nanoparticles: Promising Treatment Approach for Parkinson's Disease.
Authors:Jagaran K, Singh M
Institution:Nano-Gene and Drug Delivery Laboratory, Discipline of Biochemistry, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South Africa.
Journal:Int J Mol Sci. 2022 Aug 19;23(16):9361. doi: 10.3390/ijms23169361.

17:Research Progress of Music Therapy on Gait Intervention in Patients with Parkinson's Disease.
Authors:Wu Z, Kong L, Zhang Q
Institution:Physical Education and Sports School, Soochow University, Suzhou 215021, China.
Journal:Int J Environ Res Public Health. 2022 Aug 4;19(15):9568. doi: 10.3390/ijerph19159568.

18:Research progress in the early diagnosis of Parkinson's disease.
Authors:Xie L, Hu L
Institution:Qingdao University, Qingdao, 266071, Shandong, China. XLL961231@163.com.; Weifang Medical University, Weifang, 261053, Shandong, China.
Journal:Neurol Sci. 2022 Nov;43(11):6225-6231. doi: 10.1007/s10072-022-06316-0. Epub 2022 Aug 11.

19:Self-management Interventions for People With Parkinson Disease: Scoping Review.
Authors:Milne-Ives M, Carroll C, Meinert E
Institution:Centre for Health Technology, University of Plymouth, Plymouth, United Kingdom.
Journal:J Med Internet Res. 2022 Aug 5;24(8):e40181. doi: 10.2196/40181.

20:High-dose versus low-dose inhaled levodopa (CVT-301) in patients with Parkinson disease for the treatment of OFF episodes: a meta-analysis of randomized controlled trials.
Authors:Yan Z, Wang W, Tao X, Cheng W, Zuo G, Chen Z, Wang Z, Chen G
Institution:Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Journal:Neurol Sci. 2022 Nov;43(11):6233-6241. doi: 10.1007/s10072-022-06298-z. Epub 2022 Jul 30.

21:New Targets and New Technologies in the Treatment of Parkinson's Disease: A Narrative Review.
Authors:Montemurro N, Aliaga N, Graff P, Escribano A, Lizana J
Institution:Department of Neurosurgery, Azienda Ospedaliera Universitaria Pisana (AOUP), University of Pisa, 56100 Pisa, Italy.; Department of Neurosurgery, Hospital Nacional Guillermo Almenara Irigoyen, Lima 07035, Peru.
Journal:Int J Environ Res Public Health. 2022 Jul 20;19(14):8799. doi: 10.3390/ijerph19148799.

22:COVID-19 and Parkinsonism: A Critical Appraisal.
Authors:Cavallieri F, Fioravanti V, Bove F, Del Prete E, Meoni S, Grisanti S, Zedde M, Pascarella R, Moro E, Valzania F
Institution:Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Via Amendola 2, 42124 Reggio Emilia, Italy.
Journal:Biomolecules. 2022 Jul 11;12(7):970. doi: 10.3390/biom12070970.

23:The effects of physiotherapy treatments on dysphagia in Parkinson's disease: A systematic review of randomized controlled trials.
Authors:Wen X, Liu Z, Liu X, Peng Y, Liu H
Institution:School of Rehabilitation Medicine Gannan Medical University, Ganzhou, Jiangxi, China. Electronic address: 2429398086@qq.com.; Department of Rehabilitation Medicine, Yue Bei People's Hospital, Shaoguan, Guangdong, China. Electronic address: liuhuiyudoctor@sohu.com.
Journal:Brain Res Bull. 2022 Oct 1;188:59-66. doi: 10.1016/j.brainresbull.2022.07.016. Epub 2022 Jul 23.

24:Device-Assisted and Neuromodulatory Therapies for Parkinson's Disease: A Network Meta-Analysis.
Authors:Rajan R, Garg K, Srivastava AK, Singh M
Institution:Departments of Neurology, CN Centre, All India Institute of Medical Sciences, New Delhi, India.; Department of Neurosurgery, CN Centre, All India Institute of Medical Sciences, New Delhi, India.
Journal:Mov Disord. 2022 Sep;37(9):1785-1797. doi: 10.1002/mds.29160. Epub 2022 Jul 22.

25:Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.
Authors:Di Luca DG, Reyes NGD, Fox SH
Institution:Edmond J. Safra Program in Parkinson's Disease, Movement Disorders Clinic, Krembil Brain Institute, Toronto Western Hospital, Toronto, ON, Canada. susan.fox@uhnresearch.ca.
Journal:Drugs. 2022 Jul;82(10):1027-1053. doi: 10.1007/s40265-022-01747-7. Epub 2022 Jul 16.

26:Systematic review for the prevention and management of falls and fear of falling in patients with Parkinson's disease.
Authors:Liu WY, Tung TH, Zhang C, Shi L
Institution:Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Journal:Brain Behav. 2022 Aug;12(8):e2690. doi: 10.1002/brb3.2690. Epub 2022 Jul 14.

27:Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease.
Authors:Nwabufo CK, Aigbogun OP
Institution:Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Canada. Chukwunonso.nwabufo@usask.ca.
Journal:J Neurol. 2022 Nov;269(11):5762-5786. doi: 10.1007/s00415-022-11267-9. Epub 2022 Jul 13.

28:COVID-19 and Parkinson's Disease: Possible Links in Pathology and Therapeutics.
Authors:Tiwari S, Yadav N, Singh S
Institution:Department of Neurosciences and Ageing Biology and Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, 226031, UP, India. Sarika_singh@cdri.res.in.
Journal:Neurotox Res. 2022 Oct;40(5):1586-1596. doi: 10.1007/s12640-022-00540-4. Epub 2022 Jul 13.

29:New hope for Parkinson's disease treatment: Targeting gut microbiota.
Authors:Fan HX, Sheng S, Zhang F
Institution:Laboratory Animal Center and Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education and Key Laboratory of Basic Pharmacology of Guizhou Province, Zunyi Medical University, Zunyi, Guizhou, China.
Journal:CNS Neurosci Ther. 2022 Nov;28(11):1675-1688. doi: 10.1111/cns.13916. Epub 2022 Jul 13.

30:Icariin: A Potential Neuroprotective Agent in Alzheimer's Disease and Parkinson's Disease.
Authors:Khezri MR, Ghasemnejad-Berenji M
Institution:Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.; Department of Pharmacology and Toxicology, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran. ghasemnejad.m@umsu.ac.ir.
Journal:Neurochem Res. 2022 Oct;47(10):2954-2962. doi: 10.1007/s11064-022-03667-0. Epub 2022 Jul 8.

31:Deep brain stimulation for Parkinson's disease.
Authors:Hariz M, Blomstedt P
Institution:Department of Clinical Neuroscience, University Hospital of Umea, Umea, Sweden.
Journal:J Intern Med. 2022 Nov;292(5):764-778. doi: 10.1111/joim.13541. Epub 2022 Jul 13.

32:Therapeutic Insights on Ferroptosis in Parkinson's disease.
Authors:Thapa K, Khan H, Kanojia N, Singh TG, Kaur A, Kaur G
Institution:Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India; Chitkara School of Pharmacy, Chitkara University, Himachal Pradesh, India.
Journal:Eur J Pharmacol. 2022 Sep 5;930:175133. doi: 10.1016/j.ejphar.2022.175133. Epub 2022 Jul 2.

33:European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies.
Authors:Deuschl G, Antonini A, Costa J, Śmiłowska K, Berg D, Corvol JC, Fabbrini G, Ferreira J, Foltynie T, Mir P, Schrag A, Seppi K, Taba P, Ruzicka E, Selikhova M, Henschke N, Villanueva G, Moro E
Institution:Department of Neurology, UKSH-Kiel Campus, Christian-Albrechts-University, Kiel, Germany.; Division of Neurology, Grenoble, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.
Journal:Mov Disord. 2022 Jul;37(7):1360-1374. doi: 10.1002/mds.29066. Epub 2022 Jul 6.

34:Deep brain stimulation for Parkinson's disease-related postural abnormalities: a systematic review and meta-analysis.
Authors:Spindler P, Alzoobi Y, Kühn AA, Faust K, Schneider GH, Vajkoczy P
Institution:Department of Neurosurgery, Charite University Medicine Berlin, Chariteplatz 1, 10117, Berlin, Germany. philipp.spindler@charite.de.
Journal:Neurosurg Rev. 2022 Oct;45(5):3083-3092. doi: 10.1007/s10143-022-01830-3. Epub 2022 Jul 5.

35:Psychological outcomes of the COVID-19 pandemic in patients with Parkinson's disease: A systematic review.
Authors:Nabizadeh F, Seyedalhosseini Z, Balabandian M, Reza Rostami M
Institution:Neuroscience Research Group (NRG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: fardinnabizade1378@gmail.com.
Journal:J Clin Neurosci. 2022 Aug;102:101-108. doi: 10.1016/j.jocn.2022.06.017. Epub 2022 Jun 28.

36:Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.
Authors:Żegleń M, Śladowska K, Kawalec P, Brzostek T
Institution:Pain Research Group, Institute of Psychology, Jagiellonian University, Krakow, 30-060, Poland.; Department of Internal Medicine & Community Nursing, Faculty of Health Sciences, Institute of Nursing & Midwifery, Jagiellonian University Medical College, Krakow, 31-501, Poland.
Journal:J Comp Eff Res. 2022 Aug;11(12):889-904. doi: 10.2217/cer-2022-0031. Epub 2022 Jun 27.

37:Empowerment in people with Parkinson's disease: A scoping review and qualitative interview study.
Authors:Kang E, Friz D, Lipsey K, Foster ER
Institution:Program in Occupational Therapy, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: eunyoung@wustl.edu.; Program in Occupational Therapy, Department of Neurology, & Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: erfoster@wustl.edu.
Journal:Patient Educ Couns. 2022 Oct;105(10):3123-3133. doi: 10.1016/j.pec.2022.06.003. Epub 2022 Jun 9.

38:Prevalence and clinical aspects of depression in Parkinson's disease: A systematic review and meta‑analysis of 129 studies.
Authors:Cong S, Xiang C, Zhang S, Zhang T, Wang H
Institution:Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, China. Electronic address: congsy@s--hospital.org.
Journal:Neurosci Biobehav Rev. 2022 Oct;141:104749. doi: 10.1016/j.neubiorev.2022.104749. Epub 2022 Jun 21.

39:Epigallocatechin gallate for Parkinson's disease.
Authors:Sergi CM
Institution:National '111' Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, Wuhan, China.
Journal:Clin Exp Pharmacol Physiol. 2022 Oct;49(10):1029-1041. doi: 10.1111/1440-1681.13691. Epub 2022 Jul 23.

40:Neuroprotective approaches to halt Parkinson's disease progression.
Authors:Sola P, Krishnamurthy PT, Kumari M, Byran G, Gangadharappa HV, Garikapati KK
Institution:Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, The Nilgiris, Tamil Nadu, 643001, India.
Journal:Neurochem Int. 2022 Sep;158:105380. doi: 10.1016/j.neuint.2022.105380. Epub 2022 Jun 17.

41:Computerized cognitive training in Parkinson's disease: A systematic review and meta-analysis.
Authors:Gavelin HM, Domellöf ME, Leung I, Neely AS, Launder NH, Nategh L, Finke C, Lampit A
Institution:Academic Unit for Psychiatry of Old Age, University of Melbourne, Parkville, Australia; Department of Psychology, Umea University, Umea, Sweden.; Academic Unit for Psychiatry of Old Age, University of Melbourne, Parkville, Australia; Department of Neurology, Charite - Universitatsmedizin Berlin, Berlin, Germany; Berlin School of Mind and Brain, Humboldt-Universitat zu Berlin, Berlin, Germany. Electronic address: amit.lampit@unimelb.edu.au.
Journal:Ageing Res Rev. 2022 Sep;80:101671. doi: 10.1016/j.arr.2022.101671. Epub 2022 Jun 14.

42:Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease.
Authors:Lenka A, Di Maria G, Lamotte G, Bahroo L, Jankovic J
Institution:Department of Neurology, Medstar Georgetown University Hospital, Washington, DC, USA.; Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
Journal:Expert Rev Neurother. 2022 Jun;22(6):489-498. doi: 10.1080/14737175.2022.2091436. Epub 2022 Jun 21.

43:Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.
Authors:Prange S, Klinger H, Laurencin C, Danaila T, Thobois S
Institution:Hospices Civils de Lyon, Hopital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson, NS-PARK/FCRIN Network, 59 Boulevard Pinel, 69500, Bron, France. stephane.prange@isc.cnrs.fr.; Hospices Civils de Lyon, Hopital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson, NS-PARK/FCRIN Network, 59 Boulevard Pinel, 69500, Bron, France. stephane.thobois@chu-lyon.fr.
Journal:Drugs Aging. 2022 Jun;39(6):417-439. doi: 10.1007/s40266-022-00942-1. Epub 2022 Jun 16.

44:A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living.
Authors:Sun W, Wang Q, Yang T, Feng C, Qu Y, Yang Y, Li C, Sun Z, Asakawa T
Institution:Harbin Medical University, Harbin, China.; Institute of Neurology, Guangdong Province, The Third People's Hospital of Shenzhen, 29 Buji Bulan Road, Shenzhen, 518112, China. asakawat1971@gmail.com.
Journal:Neurol Sci. 2022 Oct;43(10):5821-5837. doi: 10.1007/s10072-022-06159-9. Epub 2022 Jun 13.

45:The association between Parkinson's disease and Sexual dysfunction: Clinical correlation and therapeutic implications.
Authors:Ng YF, Chen CY, Chia GT, Tan BBJ, Chan LL, Tan EK
Institution:Duke-NUS Medical School, 8 College Road, 169857, Singapore.; Duke-NUS Medical School, 8 College Road, 169857, Singapore; Department of Neurology, National Neuroscience Institute, 11 Jalan Tan Tock Seng, 308433, Singapore. Electronic address: gnrtek@sgh.com.sg.
Journal:Ageing Res Rev. 2022 Aug;79:101665. doi: 10.1016/j.arr.2022.101665. Epub 2022 Jun 9.

46:A step forward for LRRK2 inhibitors in Parkinson's disease.
Authors:Lewis PA
Institution:Royal Veterinary College, London NW1 0TU, UK.
Journal:Sci Transl Med. 2022 Jun 8;14(648):eabq7374. doi: 10.1126/scitranslmed.abq7374. Epub 2022 Jun 8.

47:Can Berberine Serve as a New Therapy for Parkinson's Disease?
Authors:Dadgostar E, Moghanlou M, Parvaresh M, Mohammadi S, Khandan M, Aschner M, Mirzaei H, Tamtaji OR
Institution:Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.; Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. tamtaji.or@gmail.com.
Journal:Neurotox Res. 2022 Aug;40(4):1096-1102. doi: 10.1007/s12640-022-00526-2. Epub 2022 Jun 6.

48:Interventions for preventing falls in Parkinson's disease.
Authors:Allen NE, Canning CG, Almeida LRS, Bloem BR, Keus SH, Löfgren N, Nieuwboer A, Verheyden GS, Yamato TP, Sherrington C
Institution:Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.; Institute for Musculoskeletal Health, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Journal:Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD011574. doi: 10.1002/14651858.CD011574.pub2.

49:Life style and Parkinson's disease.
Authors:Reichmann H, Csoti I, Koschel J, Lorenzl S, Schrader C, Winkler J, Wüllner U
Institution:Department of Neurology, University Hospital Dresden, Fetscherstrasse 74, 01307, Dresden, Germany. Heinz.Reichmann@ukdd.de.; Department of Neurology, University Clinic Bonn and German Center for Neurodegenerative Diseases (DZNE), 53127, Bonn, Germany.
Journal:J Neural Transm (Vienna). 2022 Sep;129(9):1235-1245. doi: 10.1007/s00702-022-02509-1. Epub 2022 May 23.

50:Effects of Nordic walking in people with Parkinson's disease: A systematic review and meta-analysis.
Authors:Salse-Batán J, Sanchez-Lastra MA, Suarez-Iglesias D, Varela S, Ayán C
Institution:Universidade de Vigo, Pontevedra, Spain.; Universidade de Vigo, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Departamento de Didacticas Especiais, Well-Move Research Group, Pontevedra, Spain.
Journal:Health Soc Care Community. 2022 Sep;30(5):e1505-e1520. doi: 10.1111/hsc.13842. Epub 2022 May 20.

51:An overview of the active clinical trials for Parkinson's disease psychosis.
Authors:Kwan C, Huot P
Institution:Neurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, QC, H3A 2B4, Canada.
Journal:Neurodegener Dis Manag. 2022 Aug;12(4):165-170. doi: 10.2217/nmt-2022-0020. Epub 2022 May 20.

52:Neuropsychiatric Symptoms in Clinically Defined Parkinson's Disease: An Updated Review of Literature.
Authors:Macías-García P, Rashid-López R, Cruz-Gómez ÁJ, Lozano-Soto E, Sanmartino F, Espinosa-Rosso R, González-Rosa JJ
Institution:Institute of Biomedical Research Cadiz (INIBICA), Cadiz, Spain.
Journal:Behav Neurol. 2022 May 9;2022:1213393. doi: 10.1155/2022/1213393. eCollection 2022.

53:How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?
Authors:Mahlknecht P, Foltynie T, Limousin P, Poewe W
Institution:Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
Journal:Mov Disord. 2022 Aug;37(8):1581-1592. doi: 10.1002/mds.29052. Epub 2022 May 12.

54:The neuroprotective roles of Dietary Micronutrients on Parkinson's disease: a review.
Authors:Rahimmi A, Tozandehjani S, Daraei M, Khademerfan M
Institution:Department of Molecular Medicine, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. khademerfan@gmail.com.
Journal:Mol Biol Rep. 2022 Aug;49(8):8051-8060. doi: 10.1007/s11033-022-07345-w. Epub 2022 May 8.

55:Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review.
Authors:Vismara M, Benatti B, Nicolini G, Cova I, Monfrini E, Di Fonzo A, Fetoni V, Viganò CA, Priori A, Dell'Osso B
Institution:Department of Mental Health, Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital, University of Milan, Via G.B. Grassi, 74, 20157, Milan, Italy. matteo.vismara@unimi.it.
Journal:BMC Neurol. 2022 May 5;22(1):169. doi: 10.1186/s12883-022-02668-4.

56:Stepping up to meet the challenge of freezing of gait in Parkinson's disease.
Authors:Lewis S, Factor S, Giladi N, Nieuwboer A, Nutt J, Hallett M
Institution:ForeFront Parkinson's Disease Research Clinic, Brain and Mind Centre, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia. profsimonlewis@gmail.com.; Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Journal:Transl Neurodegener. 2022 May 1;11(1):23. doi: 10.1186/s40035-022-00298-x.

57:Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions.
Authors:Isaacson SH, Citrome L
Institution:Director, Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, USA.; Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA.
Journal:Expert Opin Drug Saf. 2022 Jul;21(7):873-879. doi: 10.1080/14740338.2022.2069240. Epub 2022 May 3.

58:Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson's disease.
Authors:Kip E, Parr-Brownlie LC
Institution:Department of Anatomy, School of Biomedical Science, Brain Health Research Centre, Brain Research New Zealand, University of Otago, Dunedin, New Zealand. Electronic address: louise.parr-brownlie@otago.ac.nz.
Journal:Ageing Res Rev. 2022 Jun;78:101618. doi: 10.1016/j.arr.2022.101618. Epub 2022 Apr 5.

59:Contributions and Limitations of Mitochondria-Targeted and Non-Targeted Antioxidants in the Treatment of Parkinsonism: an Updated Review.
Authors:Banerjee P, Saha I, Sarkar D, Maiti AK
Institution:Department of Zoology, University of Burdwan, Burdwan, West Bengal, Pin-713104, India.; Mitochondrial Biology and Experimental Therapeutics Laboratory, Department of Zoology, University of North Bengal, District - Darjeeling, P.O. N.B.U, Raja Rammohunpur, West Bengal, Pin-734013, India. arpankumar.maiti@gmail.com.
Journal:Neurotox Res. 2022 Jun;40(3):847-873. doi: 10.1007/s12640-022-00501-x. Epub 2022 Apr 7.

60:Interventions to improve gait in Parkinson's disease: a systematic review of randomized controlled trials and network meta-analysis.
Authors:Hvingelby VS, Glud AN, Sørensen JCH, Tai Y, Andersen ASM, Johnsen E, Moro E, Pavese N
Institution:Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 165, 8200, Aarhus N, Denmark. au340287@clin.au.dk.; Clinical Ageing Research Unit, Newcastle University, Newcastle Upon Tyne, UK.
Journal:J Neurol. 2022 Aug;269(8):4068-4079. doi: 10.1007/s00415-022-11091-1. Epub 2022 Apr 5.

61:The potential applications of traditional Chinese medicine in Parkinson's disease: A new opportunity.
Authors:Chen J, Xu J, Huang P, Luo Y, Shi Y, Ma P
Institution:School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. Electronic address: maping@cdutcm.edu.cn.
Journal:Biomed Pharmacother. 2022 May;149:112866. doi: 10.1016/j.biopha.2022.112866. Epub 2022 Mar 31.

62:Acupuncture for Parkinson's disease: From theory to practice.
Authors:Fan JQ, Lu WJ, Tan WQ, Feng WC, Zhuang LX
Institution:The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong, China. Electronic address: zhuanglixing@163.com.
Journal:Biomed Pharmacother. 2022 May;149:112907. doi: 10.1016/j.biopha.2022.112907. Epub 2022 Mar 31.

63:The pathogenesis and treatment mechanism of Parkinson's disease from the perspective of traditional Chinese medicine.
Authors:Chen P, Zhang J, Wang C, Chai YH, Wu AG, Huang NY, Wang L
Institution:Basic Medical School, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China; Accreditation Center of Traditional Chinese Medicine Physician, National Administration of Traditional Chinese Medicine, Beijing, China. Electronic address: 740466982@qq.com.; School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China. Electronic address: wanglongsdu1226@163.com.
Journal:Phytomedicine. 2022 Jun;100:154044. doi: 10.1016/j.phymed.2022.154044. Epub 2022 Mar 15.

64:Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease.
Authors:Cenci MA, Skovgård K, Odin P
Institution:Basal Ganglia Pathophysiology Unit, Dept. Experimental Medical Science, Lund University, Sweden. Electronic address: Angela.Cenci_Nilsson@med.lu.se.; Department of Neurology, University Hospital, Lund, Sweden.
Journal:Neuropharmacology. 2022 Jun 1;210:109027. doi: 10.1016/j.neuropharm.2022.109027. Epub 2022 Mar 12.

65:P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease.
Authors:Hauser RA, Giladi N, Poewe W, Brotchie J, Friedman H, Oren S, Litman P
Institution:Department of Neurology, University of South Florida, Tampa, FL, USA. rhauser@usf.edu.; Pharma Two B, Rehovot, Israel.
Journal:Adv Ther. 2022 May;39(5):1881-1894. doi: 10.1007/s12325-022-02097-2. Epub 2022 Mar 10.

66:A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.
Authors:Jost WH
Institution:Parkinson-Klinik Ortenau, Kreuzbergstr. 12-16, 77709, Wolfach, Germany. w.jost@parkinson-klinik.de.
Journal:J Neural Transm (Vienna). 2022 Jun;129(5-6):723-736. doi: 10.1007/s00702-022-02465-w. Epub 2022 Feb 2.

67:Effects of dance therapy on non-motor symptoms in patients with Parkinson's disease: a systematic review and meta-analysis.
Authors:Wang LL, Sun CJ, Wang Y, Zhan TT, Yuan J, Niu CY, Yang J, Huang S, Cheng L
Institution:School of Nursing, Anhui University of Chinese Medicine, No. 103 Meishan Street, Hefei, 230031, Anhui, China.; School of Humanities and International Educational Exchange, Anhui University of Chinese Medicine, No. 103 Meishan Street, Hefei, 230031, Anhui, China.
Journal:Aging Clin Exp Res. 2022 Jun;34(6):1201-1208. doi: 10.1007/s40520-021-02030-7. Epub 2022 Jan 29.

68:Clinical Review of Smartphone Applications in Parkinson's Disease.
Authors:Tripathi S, Malhotra A, Qazi M, Chou J, Wang F, Barkan S, Hellmers N, Henchcliffe C, Sarva H
Institution:Department of Neurology, New York-Presbyterian Hospital/Weill Cornell Medical Center.
Journal:Neurologist. 2022 Jul 1;27(4):183-193. doi: 10.1097/NRL.0000000000000413.

69:New approaches to treatments for sleep, pain and autonomic failure in Parkinson's disease - Pharmacological therapies.
Authors:Rukavina K, Batzu L, Leta V, Chaudhuri KR
Institution:Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience at King's College London, London, United Kingdom; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, United Kingdom.; Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience at King's College London, London, United Kingdom; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, United Kingdom; NIHR Mental Health Biomedical Research Centre and Dementia Biomedical Research Unit, South London and Maudsley NHS Foundation Trust and King's College London, United Kingdom. Electronic address: ray.chaudhuri@kcl.ac.uk.
Journal:Neuropharmacology. 2022 May 1;208:108959. doi: 10.1016/j.neuropharm.2022.108959. Epub 2022 Jan 17.

70:Dietary Antioxidants and Risk of Parkinson's Disease: A Systematic Review and Dose-Response Meta-analysis of Observational Studies.
Authors:Talebi S, Ghoreishy SM, Jayedi A, Travica N, Mohammadi H
Institution:Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran.; Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
Journal:Adv Nutr. 2022 Oct 2;13(5):1493-1504. doi: 10.1093/advances/nmac001.

71:Parkinson's disease and intensive exercise therapy - An updated systematic review and meta-analysis.
Authors:Gamborg M, Hvid LG, Dalgas U, Langeskov-Christensen M
Institution:Exercise Biology, Department of Public Health, Aarhus University, Aarhus, Denmark.
Journal:Acta Neurol Scand. 2022 May;145(5):504-528. doi: 10.1111/ane.13579. Epub 2022 Jan 8.

72:Parkinson and depression: review and outlook.
Authors:Laux G
Institution:Institute of Psychological Medicine (IPM), Soyen, Germany. ipm@ipm-laux.de.
Journal:J Neural Transm (Vienna). 2022 Jun;129(5-6):601-608. doi: 10.1007/s00702-021-02456-3. Epub 2022 Jan 4.

73:The effect of Tai Chi on functional mobility, balance and falls in Parkinson's disease: A systematic review and meta-analysis of systematic reviews.
Authors:Aras B, Seyyar GK, Fidan O, Colak E
Institution:Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Kutahya Health Sciences University, Kutahya, Turkey. Electronic address: dpuaras@yahoo.com.; Faculty of Medicine, Department of Biostatistics, Osmangazi University, Eskisehir, Turkey.
Journal:Explore (NY). 2022 Jul-Aug;18(4):402-410. doi: 10.1016/j.explore.2021.12.002. Epub 2021 Dec 13.

74:The subjective experience of family caregivers of people living with Parkinson's disease: a meta-ethnography of qualitative literature.
Authors:Chen Y, Zhou W, Hou L, Zhang X, Wang Q, Gu J, Zhang R, Yang H
Institution:School of Nursing, Shanxi Medical University, No.56, Xinjian South Road, Yingze District, Taiyuan, Shanxi, China. d17835154117@126.com.
Journal:Aging Clin Exp Res. 2022 May;34(5):959-970. doi: 10.1007/s40520-021-01995-9. Epub 2021 Oct 14.

75:Adjusting to living with Parkinson's disease; a meta-ethnography of qualitative research.
Authors:Wieringa G, Dale M, Eccles FJR
Institution:Faculty of Health and Medicine, Division of Health Research, Furness College, Lancaster University, Lancaster, UK.
Journal:Disabil Rehabil. 2022 Nov;44(23):6949-6968. doi: 10.1080/09638288.2021.1981467. Epub 2021 Sep 30.

76:Implications of dopaminergic medication withdrawal in Parkinson's disease.
Authors:Koschel J, Ray Chaudhuri K, Tönges L, Thiel M, Raeder V, Jost WH
Institution:Parkinson-Klinik Ortenau, Kreuzbergstr. 12, 77709, Wolfach, Germany. W.Jost@parkinson-klinik.de.
Journal:J Neural Transm (Vienna). 2022 Sep;129(9):1169-1178. doi: 10.1007/s00702-021-02389-x. Epub 2021 Jul 29.

77:Heart Matters: Cardiac Dysfunction and Other Autonomic Changes in Parkinson's Disease.
Authors:Gonçalves VC, Cuenca-Bermejo L, Fernandez-Villalba E, Martin-Balbuena S, da Silva Fernandes MJ, Scorza CA, Herrero MT
Institution:Clinical & Experimental Neuroscience (NiCE), Biomedical Research Institute of Murcia (IMIB- Arrixaca), Murcia, Spain.
Journal:Neuroscientist. 2022 Dec;28(6):530-542. doi: 10.1177/1073858421990000. Epub 2021 Feb 15.

78:Neuroinflammation in Parkinson's Disease: Triggers, Mechanisms, and Immunotherapies.
Authors:Wang T, Shi C, Luo H, Zheng H, Fan L, Tang M, Su Y, Yang J, Mao C, Xu Y
Institution:Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Journal:Neuroscientist. 2022 Aug;28(4):364-381. doi: 10.1177/1073858421991066. Epub 2021 Feb 12.

79:Treating hallucinations in Parkinson's disease.
Authors:Powell A, Matar E, Lewis SJG
Institution:ForeFront Parkinson's Disease Research Clinic, Brain and Mind Centre, School of Medical Sciences, the University of Sydney, Camperdown, Australia.
Journal:Expert Rev Neurother. 2022 Jun;22(6):455-468. doi: 10.1080/14737175.2021.1851198. Epub 2020 Dec 14.

For a FREE PREVIEW of the Medifocus Guidebook on Parkinson's Disease click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Parkinson's Disease click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Parkinson's Disease...
at a Special 20% Discount


Medifocus Guidebook on Parkinson's Disease

Updated: January 18, 2023
194 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Parkinson's Disease is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $37.45
  • Less 20% Discount = - $7.10
  • Discounted Price = $30.35(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $31.20
  • Less 20% Discount = - $6.45
  • Discounted Price = $24.75

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

PD940997556

Coupon Expires: March 3, 2023



What Our Customers Are Saying...

"I ordered the MediFocus Guidebook on Parkinson's Disease for my father who has had this condition for about 15 years. It was extremely useful to learn about the medications that are used to treat Parkinson's as well as the side-effects. I had read a lot of articles about Parkinson's on the Internet but they were all very general and vague. Your Guidebook provided excellent and comprehensive information from the medical perspective. Thanks for a very useful resource that is much needed today on the Web."
M.L.
Russelsheim, Germany


"I found your Guidebook on Parkinson's to be very informative for me, the patient, and for my husband. I am in the process of changing my medication and the book explained more to me than the doctor attempted to. I am now more aware of what to expect. It also offered valuable advice for the caregiver. Thank you."
M.N.
Palm Spring, California


"The Medifocus Guide to Parkinson's Disease was useful, informative, and allowed me to grasp the current fundamentals of treatment. I have recommended it to two of my ex-patients whom I know will find it readable and helpful to their needs."
G.B.
Research Triangle Park, NC



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2023 Medifocus, Inc. All rights reserved.